摘要目的 观察玻璃体腔注射雷珠单抗(IVR)联合曲安奈德(TA)或激光光凝治疗视网膜分支静脉阻塞(BRVO)继发黄斑水肿的安全性及有效性.方法 回顾性研究.临床确诊为BRVO继发黄斑水肿的31例患者31只眼纳入研究.所有患者均行最佳矫正视力(BCVA)、荧光素眼底血管造影(FFA)及光相干断层扫描(OCT)检查.视力检查采用标准对数视力表进行,并将结果转换为最小分辨角对数(logMAR)视力记录.患眼平均logMAR BCVA为(0.74±0.36),平均中央视网膜厚度(CRT)为(484.48±164.81) μm.所有患者均行常规玻璃体腔注射10 mg/ml的雷珠单抗0.05 ml(含雷珠单抗0.5 mg).出现黄斑水肿时,按需进行IVR治疗;第3次IVR治疗时黄斑水肿消退不明显者同时联合TA注射治疗.OCT检查发现黄斑水肿明显消退时,给予黄斑激光光凝治疗;FFA检查发现周边视网膜出现无灌注区,行周边视网膜激光光凝治疗.患眼接受雷珠单抗平均注射次数为(3.52±2.01)次;联合注射TA治疗15只眼,平均注射次数为(0.84±1.21)次;联合激光光凝治疗21只眼,平均次数为(0.97±0.95)次.先后接受了IVR联合TA和激光光凝这3种治疗12只眼.所有患者均随访1年.对比分析患眼治疗前后logMAR BCVA及CRT的变化情况.结果 患眼平均logMAR BCVA为(0.42±0.33).治疗前后logMAR BCVA比较,差异有统计学意义(t=6.611,P=0.000).治疗后视力较治疗前平均提高了(2.90±3.07)行.31只眼中,视力提高3行及以上者20只眼,占64.52％.患眼平均CRT为(326.19±117.80) μm.治疗后CRT较治疗前平均降低了(333.58±134.17) μm.治疗前后CRT比较,差异有统计学意义(t=4.514,P=0.000).31只眼中,CRT降低在100μm以上者17只眼,占54.84％.随访期间所有患眼均未发生白内障加重、眼内炎、视网膜脱离等严重并发症.结论 IVR联合TA或激光光凝治疗BRVO继发黄斑水肿有良好的疗效及安全性,可以明显提高患者视力并减轻黄斑水肿.

abstractsObjective To investigate the efficacy and safety of intravitreal ranibizumab and (or) triamcinolone combined with laser photocoagulation for macular edema secondary to branch retinal vein occlusion (BRVO) during one year period.Methods The data of 31 eyes from 31 consecutive patients with macular edema secondary to BRVO during one year follow-up visit were retrospectively analyzed.Mean best corrected visual acuity (BCVA) logMAR was (0.74±0.36) and mean central retinal thickness (CRT) was (484.48± 164.81) μm at baseline.All patients received standardized clinical comprehensive examinations including vision,intraocular pressure and optical coherence tomography for diagnosis before treatment.All patients received intravitreal injections of 0.5 mg ranibizumab (0.05 ml) at first visit.The continue PRN treatment were based on the visual acuity changes and the optical coherence tomography findings.Eyes received combined triamcinolone acetonide 0.05 ml (40 mg/ml) and ranibizumab for macular edema recurrence after two injections of ranibizumab and received laser photocoagulation during 10-14 days after third injections of ranibizumab.Mean injection of ranibizumab was 3.52± 2.01,15 eyes with triamcinolone acetonide (0.84 ± 1.21),21 eyes with laser photocoagulation (0.97± 0.95) and 12 eyes with three treatment.Compared the visual acuities and CRTs of the first and the last visits by statistical analysis.Results Mean visual acuity improved significantly to 0.42±0.33 logMAR (t=6.611,P=0.000).Mean improvement of visual acuity was 2.90± 3.07 lines.A gain of three or more logarithmic lines was evaluated in 20/31 eyes (64.52％) at the last visit.Mean CRT was (326.19± 117.80) μm (t=4.514,P=0.000).Mean reduction of CRT was (333.58±134.17) μm.A decrease of 100 μm of CRT was evaluated in 17/31 eyes (54.84％).No severe ocular and systematic side effect was found.Conclusion The efficacy and safety of intravitreal ranibizumab and (or) triamcinolone combined with laser photocoagulation for macular edema secondary to BRVO were assured.